Physician profile
Mark Dagdagan
NPI 1831180587
$3,157.53
in general payments reported to CMS, 2019-2025
19 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $242 · 2021: $401 · 2022: $544 · 2023: $381 · 2024: $687 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.05 | 2019-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $441.68 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $337.08 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $238.25 | 2021-2025 | Andexxa, Farxiga |
| Nestle Healthcare Nutrition INC. | $208.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.14 | 2019-2025 | Jardiance, Synjardy |
| Daiichi Sankyo INC. | $157.53 | 2023-2024 | Injectafer |
| Lilly USA, LLC | $132.80 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $118.16 | 2023 | Eliquis |
| Organogenesis INC. | $104.01 | 2024 | Puraply Wound Matrix |
| Abbott Laboratories | $94.81 | 2023 | Cardiomems |
| Medtronic, INC. | $85.00 | 2023 | Contour 3d |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.36 | 2020-2024 | Xifaxan |
| Pfizer INC. | $32.61 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $27.18 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.27 | 2025 | |
| Abbvie INC. | $21.11 | 2021 | |
| Merck Sharp & Dohme LLC | $20.86 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Amgen INC. | $15.65 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dagdagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.